Endocrinology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Study Finds That ONGLYZA (saxagliptin) When Added To Metformin Was Non-Inferior To JANUVIA When Added To Metformin In Reducing Hemoglobin In Adults With Type 2 Diabetes Mellitus
Bristol Myers-Squibb Company, 10/06/09

Results from an 18–week phase 3b study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy alone found that the addition of treatment with ONGLYZA™ 5 mg per day achieved the primary objective of demonstrating non–inferiority compared to the addition of treatment with JANUVIA 100 mg per day in reducing HbA1c from baseline. In this study, overall adverse events were reported at a similar rate for individuals taking ONGLYZA 5 mg plus metformin and JANUVIA 100 mg plus metformin.